公开(公告)号：CA2488635A1

公开(公告)日：2003-12-24

申请号：CA2488635

申请日：2003-06-11

Applicant: ABBOTT LAB

Inventor： VASUDEVAN ANIL ,  WODKA DARIUSZ ,  BLACKBURN CHRISTOPHER ,  MULHERN MATHEW M ,  LAMARCHE MATTHEW J ,  FREEMAN JENNIFER C ,  SOUERS ANDREW J ,  MAGUIRE MARTIN ,  BROWN JAMES ,  LYNCH JOHN K ,  IYENGAR RAJESH ,  CULLIS COURTNEY A ,  LEE JENNIFER G ,  GAO JU ,  PATANE MICHAEL A ,  LAI SU-JEN

IPC: C07D403/14 ,  A61K31/453 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/517 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P5/00 ,  A61P15/00 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P43/00 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D451/04 ,  A61K31/4468

Abstract: This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula (I): where m is zero or one, n is zero to two, Y is oxygen or -N (R9 )- , R1, R2, R3, R4, R5, R9, and Ring A are defined in the specification. Coumarin and quinolone compounds where R1 and R2 together form a fused benzo ring are preferred. The invention also provides compounds of formula (VI) where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.

公开(公告)号：CA2488635C

公开(公告)日：2012-10-23

申请号：CA2488635

申请日：2003-06-11

Applicant: ABBOTT LAB

Inventor： BLACKBURN CHRISTOPHER ,  LAI SU-JEN ,  CHE JENNIFER L ,  MAGUIRE MARTIN ,  PATANE MICHAEL A ,  LAMARCHE MATTHEW J ,  CULLIS COURTNEY A ,  BROWN JAMES ,  VASUDEVAN ANIL ,  FREEMAN JENNIFER C ,  MULHERN MATHEW M ,  LYNCH JOHN K ,  GAO JU ,  WODKA DARIUSZ ,  SOUERS ANDREW J ,  IYENGAR RAJESH ,  VERZAL MARY KATHERINE ,  KYM PHILIP R

IPC: C07D403/14 ,  C07D405/14 ,  A61K31/4468 ,  A61K31/453 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/517 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P5/00 ,  A61P15/00 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P43/00 ,  C07D401/14 ,  C07D405/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D451/04

Abstract: This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula (I): where m is zero or one, n is zero to two, Y is oxygen or -N (R9)-, R1, R2, R3, R4, R5, R9, and Ring A are defined in the specification. Coumarin and quinolone compounds where R1 and R2 together form a fused benzo ring are preferred. The invention also provides compounds of formula (VI) where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.